Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

被引:33
作者
Hijazi, Ziad [1 ,2 ]
Lindahl, Bertil [1 ,2 ]
Oldgren, Jonas [1 ,2 ]
Andersson, Ulrika [1 ]
Lindback, Johan [1 ]
Granger, Christopher B. [4 ]
Alexander, John H. [4 ]
Gersh, Bernard J. [5 ]
Hanna, Michael [6 ]
Harjola, Veli-Pekka [7 ]
Hylek, Elaine M. [8 ]
Lopes, Renato D. [4 ]
Siegbahn, Agneta [1 ,3 ]
Wallentin, Lars [1 ,2 ]
机构
[1] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala Sci Pk, SE-75237 Uppsala, Sweden
[2] Uppsala Univ, Dept Med Sci, Cardiol, Uppsala, Sweden
[3] Uppsala Univ, Dept Med Sci, Clin Chem, Uppsala, Sweden
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Mayo Clin, Coll Med, Rochester, MN USA
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Helsinki Univ Cent Hosp, Div Emergency Care, Dept Med, Helsinki, Finland
[8] Boston Univ, Med Ctr, Boston, MA USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2017年 / 6卷 / 06期
关键词
atrial fibrillation; cardiac biomarkers; natriuretic peptide; risk score; stroke; troponin; TERM INDIVIDUAL VARIATION; ACUTE CORONARY SYNDROMES; TROPONIN-I; RISK-ASSESSMENT; THROMBOEMBOLIC EVENTS; NATRIURETIC PEPTIDE; HEART-FAILURE; APIXABAN; ASSAY; REDUCTION;
D O I
10.1161/JAHA.116.004851
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background--Cardiac biomarkers are independent risk markers in atrial fibrillation, and the novel biomarker-based ABC stroke score (age, biomarkers, and clinical history of prior stroke) was recently shown to improve the prediction of stroke risk in patients with atrial fibrillation. Our aim was to investigate the short-term variability of the cardiac biomarkers and evaluate whether the ABC stroke risk score provides a stable short- term risk estimate. Methods and Results--According to the study protocol, samples were obtained at entry and also at 2 months in 4796 patients with atrial fibrillation followed for a median of 1.8 years in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Cardiac troponin I, cardiac troponin T, and N-terminal pro-B-type natriuretic peptide were measured with high-sensitivity immunoassays. Associations with outcomes were evaluated by Cox regression. C indices and calibration plots were used to evaluate the ABC stroke score at 2 months. The average changes in biomarker levels during 2 months were small ( median change cardiac troponin T +2.8%, troponin I +2.0%, and N-terminal pro-B-type natriuretic peptide +13.5%) and within-subject correlation was high ( all >= 0.82). Repeated measurement of cardiac biomarkers provided some incremental prognostic value for mortality but not for stroke when combined with clinical risk factors and baseline levels of the biomarkers. Based on 8702 person-years of follow-up and 96 stroke/systemic embolic events, the ABC stroke score at 2 months achieved a similar C index of 0.70 (95% CI, 0.65-0.76) as compared with 0.70 (95% CI, 0.65-0.75) at baseline. The ABC stroke score remained well calibrated using predefined risk classes. Conclusions--In patients with stable atrial fibrillation, the variability of the cardiac biomarkers and the biomarker- based ABC stroke score during 2 months are small. The prognostic information by the ABC stroke score remains consistent and well calibrated with similar good predictive performance if patients are retested after 2 months. Clinical Trial Registration --URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.
引用
收藏
页数:12
相关论文
共 30 条
[11]   Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy [J].
Hijazi, Ziad ;
Oldgren, Jonas ;
Andersson, Ulrika ;
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Hohnloser, Stefan H. ;
Reilly, Paul A. ;
Siegbahn, Agneta ;
Yusuf, Salim ;
Wallentin, Lars .
HEART, 2014, 100 (15) :1193-1200
[12]   High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial [J].
Hijazi, Ziad ;
Siegbahn, Agneta ;
Andersson, Ulrika ;
Granger, Christopher B. ;
Alexander, John H. ;
Atar, Dan ;
Gersh, Bernard J. ;
Mohan, Puneet ;
Harjola, Veli-Pekka ;
Horowitz, John ;
Husted, Steen ;
Hylek, Elaine M. ;
Lopes, Renato D. ;
McMurray, John J. V. ;
Wallentin, Lars .
CIRCULATION, 2014, 129 (06) :625-634
[13]   High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin [J].
Hijazi, Ziad ;
Wallentin, Lars ;
Siegbahn, Agneta ;
Andersson, Ulrika ;
Alexander, John H. ;
Atar, Dan ;
Gersh, Bernard J. ;
Hanna, Michael ;
Harjola, Veli Pekka ;
Horowitz, John D. ;
Husted, Steen ;
Hylek, Elaine M. ;
Lopes, Renato D. ;
McMurray, John J. V. ;
Granger, Christopher B. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (01) :52-61
[14]   N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) [J].
Hijazi, Ziad ;
Wallentin, Lars ;
Siegbahn, Agneta ;
Andersson, Ulrika ;
Christersson, Christina ;
Ezekowitz, Justin ;
Gersh, Bernard J. ;
Hanna, Michael ;
Hohnloser, Stefan ;
Horowitz, John ;
Huber, Kurt ;
Hylek, Elaine M. ;
Lopes, Renato D. ;
McMurray, John J. V. ;
Granger, Christopher B. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (22) :2274-2284
[15]   Biomarkers in atrial fibrillation: a clinical review [J].
Hijazi, Ziad ;
Oldgren, Jonas ;
Siegbahn, Agneta ;
Granger, Christopher B. ;
Wallentin, Lars .
EUROPEAN HEART JOURNAL, 2013, 34 (20) :1475-+
[16]   Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy [J].
Hijazi, Ziad ;
Oldgren, Jonas ;
Andersson, Ulrika ;
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Hohnloser, Stefan H. ;
Reilly, Paul A. ;
Vinereanu, Dragos ;
Siegbahn, Agneta ;
Yusuf, Salim ;
Wallentin, Lars .
CIRCULATION, 2012, 125 (13) :1605-U71
[17]   Narrative review: Alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded [J].
Jeremias, A ;
Gibson, CM .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (09) :786-791
[18]   Biochemical indicators of cardiac and renal function in a healthy elderly population [J].
Johnston, N ;
Jernberg, T ;
Lindahl, B ;
Lindbäck, J ;
Stridsberg, M ;
Larsson, A ;
Venge, P ;
Wallentin, L .
CLINICAL BIOCHEMISTRY, 2004, 37 (03) :210-216
[19]   2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [J].
Kirchhof, Paulus ;
Benussi, Stefano ;
Kotecha, Dipak ;
Ahlsson, Anders ;
Atar, Dan ;
Casadei, Barbara ;
Castella, Manuel ;
Diener, Hans-Christoph ;
Heidbuchel, Hein ;
Hendriks, Jeroen ;
Hindricks, Gerhard ;
Manolis, Antonis S. ;
Oldgren, Jonas ;
Popescu, Bogdan Alexandru ;
Schotten, Ulrich ;
Van Putte, Bart ;
Vardas, Panagiotis .
EUROPEAN HEART JOURNAL, 2016, 37 (38) :2893-+
[20]   Evaluation of four sensitive troponin assays for risk assessment in acute coronary syndromes using a new clinically oriented approach for comparison of assays [J].
Lindahl, Bertil ;
Eggers, Kai M. ;
Venge, Per ;
James, Stefan .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (09) :1859-1864